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INTRODUCTION 
In spite of major advances in medical care, infections 
caused by Streptococcus pneurnorziae continue to be fre- 
quent all over the world and are associated with signi- 
ficant morbidity or mortality [l-51. Thus, S. pneurnoniae 
has remained a major cause of community-acquired 
pneumonia, acute otitis media and sinusitis, exacerbation 
of chronic bronchitis, and acute bacterial meningitis 
[1,3]. The mortality rate in adult patients suffering from 
severe pneumococcal pneumonia or meningitis may be 
as high as 30% [1,6]. 
Over recent years we have seen significant changes 
in the epidemiology of pneumococcal infections, such 
as: first, the emergence of S. pneurnoniae strains resistant 
to penicillin and other antimicrobials [7-131, which has 
complicated the treatment of such infections; second, 
the increasing prevalence of pneumococcal infections 
in specific groups of patients such as those with HIV 
infection and other immunosuppressive conditions 
[ 14-1 61; and third, the advanced age of the population, 
since elderly people are at higher risk for pneumococcal 
infections [l]. 
Several options appear to be available to respond to 
this situation. First, a more appropriate and rational use 
of antibiotics may significantly reduce the resistance 
rates [17,18]. Second, the availability of the new 
antimicrobial agents (e.g. new quinolones) may improve 
the treatment options for pneumococcal infections 
[19-22]. Third, future vaccine developments may help 
in prevention strategies [23,24]. 
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O n  the basis of new discoveries in the field 
of immune response to pneumococcal infection and 
carriage, we may anticipate that the implementation of 
preventive strategies such as pneumococcal vaccination 
programs (251 (using the polysaccharide pneumococcal 
vaccines and/or conjugate pneumococcal vaccines and/ 
or protein pneumococcal vaccines) may diminish 
infection rates and, in the most optimistic scenario, may 
even 'eradicate' the pneumococcus from the naso- 
pharynx, and, consequently prevent pneumococcal 
infections altogether. 
In this review, we shall try to provide an update 
on the most significant current findings of antibiotic 
resistance in S. pneumoniae as they bear on the treatment 
options of pneumococcal infections. Our  remarks 
will be restricted to the treatment of pneumonia and 
meningitis, primarily in adult patients. 
ANTIBIOTIC RESISTANCE 
Over the last four decades, many strains of S. pneu- 
moniae have become resistant to various classes of anti- 
biotics, the only exception being vancomycin [26-391. 
Resistance to tetracycline, penicillin and erythromycin, 
singly or in combination, appeared in S. pneurnoniue in 
the 1960s, and resistance to chloramphenicol and co- 
trimoxazole in the 1970s. Of special concern was 
the first description of multiresistant strains (including 
high-level resistance to penicillin), which were initially 
reported in the 1970s in South Africa [26,27]. During 
the 1980s and the 1990s, the pneumococcus has 
become resistant to cephalosporins and quinolones 
[13,20,22], and there has been a spread of penicillin- 
resistant and multiresistant pneumococci all over the 
world [8,11,20]. 
Currently, the prevalence and patterns of antibiotic 
resistance in S. pneumoniae vary widely from one 
country to another, and children with otitis media tend 
to harbor strains with higher levels of resistance 1121. 
Rates of resistance to penicillin have increased in 
countries such as the USA [34], Canada [29], Korea 
[38], France [40], Hungary [28] and Spain [13] (Table 
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l), but have remained at very low levels in Germany 
[41], Belgium [42], England and Wales [43]. 
It is important to know that when S. pneumoniae 
shows an increased MIC for penicillin G, it also shows 
increased MICs for other j3-lactams, although to 
hfferent degrees [44-461. Thus, when compared with 
the MICs of penicdhn G, the MICs of amoxycillin and 
also the MICs of cephalosporins such as cefotaxime, 
ceftriaxone, cefpirome and cefepime are usually 1-2 
dilutions smaller. The MICs of carbapenem such as 
imipenem or meropenem are stdl lower by 1-2 
dilutions when compared to the MIC of cefotaxime. 
On the other hand, other cephalosporins such as 
ceftazidime, cefaclor and cefixime have very poor in 
vitro activity against penicillin-resistant strains [44]. 
Moreover, penicillin-resistant strains are likely to be 
multiresistant: they often show resistance to other 
antibiotics such as macrolides, tetracycline, chloram- 
phenicol and co-trimoxazole [12,13]. To date, there are 
no reports of pneumococcal strains resistant to vanco- 
mycin or teicoplanin, and only a few strains have been 
reported to be resistant to rifampin [12]. 
The distribution of the serogroups/serotypes of S. 
pneumoniae may vary widely according to the age of the 
population and the geographic area [13], which may 
have important implications for vaccine development 
and vaccination strategies. However, the most frequent 
serogroups/serotypes classically associated with penicillin 
resistance and often showing multiresistance are the 
following: 23, 19, 14, 9 and 6. 
Some reports have shown that prior p-lactam 
antibiotic therapy may be an identifiable risk factor for 
Table 1 Antibiotic resistance in Streptococcus pneumoniae 
the carriage stage or infection caused by penicillin- 
resistant pneumococcal strains [17,18,47,48]. More- 
over, a recent study has shown that a low daily dose and 
a long duration of treatment with a B-lactam antibiotic 
increases the risk for carriage of penicillin-resistant 
pneumococci [18]. One may speculate that this 
selective pressure exerted by the enormous (and often 
inappropriate) antibiotic consumption has played an 
important role in the rapid emergence and global 
spread of antibiotic-resistant pneumococci [49-511. 
NEW POTENTIAL AGENTS FOR TREATING 
PNEUMOCOCCAL INFECTIONS 
The emergence of multiresistant pneumococci has 
stimulated research into new antimicrobial drugs, in- 
cluding new-generation quinolones and other com- 
pounds. 
Thus, although old quinolones, such as cipro- 
floxacin and ofloxacin, have little activity against S. 
pneumoniae, some of the newest agents, such as trova- 
floxacin, clinafloxacin, sparfloxacin and grepafloxacin, 
are very active compounds against both penicillin- 
resistant and -susceptible strains [20,22,52,53]. In 
addition, these new quinolones have very good activity 
against almost all other common bacterial respiratory 
pathogens and may play an important role in the 
therapy of adult patients with severe community- 
acquired pneumonia [ 191. 
However, extensive and inappropriate use of these 
quinolones may also be associated with rapid emer- 
gence of resistance. Thus, nowadays, there are a few 
~~~~ 
MIC (mg/L) % resistance MIC9o 
~~ 
Penicdin 
Intermediate 
High resistance 
Intermediate 
High resistance 
Co-trimoxazole 
Tetracycline 
Chloramphenicol 
Erythromycin 
Vancomycin 
Ciprofloxacin 
Ofloxacin 
Spadoxacin 
Trovalloxacin 
Cefotaxime 
>=0.12 
>=2.0 
>=1.0 
1 .o 
> =2 
> =4/76 
> =4 
>=8 
> = 1  
> 1  
> =4 
> =8 
> = 2  
> =4 
0.12-1 .o 
51.1 
23.4 
27.7 
29.6 
17.6 
12 
49.6 
41 
27.9 
28.4 
0 
3.1 
2.1 
2.1 
0.6 
2 
1 
4/76 
> 64 
16 
>128 
0.5 
3 
3 
- - 
0.25 
0.12 
Four hundred and seventy-six pneumococcal strains consecutively isolated from adult patients in Bellvitge Hospital, Barcelona (Spain) during 
the period 1996-97. The isolates were from blood (n=75), upper respiratory tract (n=359), lower respiratory tract (n= 18), cerebrospinal 
fluid (n=7), and other origins (n=17). Data taken from Linares et al [22]. 
MIC breakpoints accordmg to NCCLS [81]. 
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pneumococcal strains which are resistant to these agents 
(Table 1). The mechanisms of quinolone resistance in 
S.  prieumoniae usually involve mutations in the parC 
gene of topoisomerase IV, which produces low-level 
resistance, but when it is associated with mutations in 
the gyrA gene, then the pneumococcus may acquire 
high-level resistance [21,22]. It is also important to 
know that some of these new quinolones have been 
associated with adverse effects [21]. 
There are several other drugs that are under 
investigation for the treatment of pneumococcal 
infections. Streptogramins, such as the combination of 
quinupristin and dalfoprisitin (Synercid), are very active 
compounds against penicillin- and erythromycin- 
resistant strains [54]. Other compounds which appear 
Table 2 Treatment of adult pneumococcal pneumonia 
promising for the treatment of multiresistant pneu- 
mococcal infections are tricyclic p-lactams such as 
safetrinem, new glycopeptides, oxazolidinones, and 
rifabutin [54,55]. 
CLINICAL AND THERAPEUTIC IMPLICATIONS OF 
RESISTANCE 
In order to be clinically relevant, the in vitro definition 
of resistance should be associated with poor clinical 
outcomes. Thus the definition of breakpoints for each 
antimicrobial and for each microorganism is an 
important and difficult decision that should be made by 
expert committees such as the National Committee for 
Clinical Laboratory Standards (NCCLS). 
Initial therapy 
Mild/moderate pneumonia 
Primary: oral amoxycillin 1 g/8 h 
Alternative: oral amoxycillin-clavnlanate 1 g/8 h or oral cefuroxime 750 mg/8-12 h or oral macrolide (e.g. erythromycin, clarithromycin) 
or IM penicillin procaine 1.2 mU/12 h 
Severe pneumonia 
Primary: i.v. ceftriaxone 1-2 g/24 h or IV cefotaxime 1-2 g/8 h or IV amoxycillin-clavulanate 2 g/8 h (2 )  IV erythromycin 1 g/6 h 
Alternative: IV cefpirome 1-2 g/12 h or IV cefepime 1-2 g/8-12 h or IV imipenem 500 mg/6 h or JV meropenem 1 g/8 h or IV 
vancomycin 1 g/12 h or a new quinolone (e.g. trovafloxacin or sparfloxacin) 
Modifications based on susceptibility studies 
Strains susceptible to penicillin (MICs < =0.06 mg/L) 
IV penicillin G 1 inU/4 h or IV ampicillin 1 g/6 h 
Penicillin MICs 0.12-3.0 mg/L 
IV penicillin G 2 mU/4 h or IV ampicillin 2 g/6 h 
Penicillin MICs > =4.0 mg/L 
Based on clinical response to initial therapy and antibiotic susceptibility 
Dosage recommendations are approximate values for an adult patient of 6&70 kg. 
Table 3 Treatment of adult pneumococcal meningitis 
Initial therapy 
Primary: IV cefotaxime 300-400 mg/kg per day (5-6 g/6 h) (maximum 24 g/day) (5 )  IV vancomycin 30 mg/kg per day (1 g/12 h) 
Alternative: IV vancomycin (+) IV rifampin 900 mg/24 h or IV cefotaxime (+) IV rifampin 
Modification when susceptibility studies are known 
Strains susceptible to penicillin” 
IV penicillin G 3-4 mU/4 h 
Strains non-susceptible (penicillin MICs > =0.12 mg/L): 
Strains susceptible to cefotaxime 
IV cefotaxime 200 mg/kg per day (3-4 g/6 h) or IV ceftriaxone 50 mg/kg per day (4 g/24 h) 
Strains non-susceptible (cefotaxime MICs > = 1 .O mg/L) 
IV cefotaxime 300-400 nig/kg per day (5-6 g/6 h) (maximum 24 g/day) (2) IV vancomycin 30 mg/kg per day (1 g/12 h) or other 
alternative based on susceptibility studies (e.g. vancomycin (+) rifampin or meropenem or a new quinolone) 
’Dosage recommendations are approximate values for an adult patient of 60-70 kg. 
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An important parameter to be considered is the 
therapeutic index, which is defined as the ratio of drug 
concentration achievable at the site of infection and the 
drug concentration that inhibits growth (MIC). 
In the case of meningitis, the relevant parameter is 
actually the drug concentration that lulls the bacteria 
(minimal bactericidal concentration, MBC), and it has 
been suggested that for penicillin and most other p- 
lactams the therapeutic index should be 10-fold or 
higher. Moreover, the bactericidal activity and efficacy 
of p-lactam antibiotics are dependent on the time for 
which their concentrations exceed the MIC (time > 
MIC), which should be at least 40-50% of the dosing 
interval [56]. In contrast, the efficacy of other drugs 
such as aminoglycosides and quinolones depends on 
high peak concentration and their prolonged post- 
antibiotic effect 1571. 
There is convincing evidence that the emergence of 
pneumococcal strains with decreased susceptibility to 
penicillin (even those with intermediate resistance) has 
had a real impact on the outcome of meningitis. The 
levels of penicillin achieved in the cerebrospinal fluid 
(CSF) are close to or even lower than the MICs of inter- 
mediately penicillin-resistant strains, and this explains the 
number of pediatric and adult patients with meningitis 
who fail on penicfin therapy [54,58,62,63]. 
When the infection is located outside the central 
nervous system, such as in the case of pneumonia or 
bacteremia, resistance to penicillin is not associated 
with poor outcomes such as failure to respond to 
therapy or higher mortality rate [6,64-691. This can be 
explained by the fact that the levels of penicillin (or 
related p-lactams such as amoxycillin or ampicillin) 
achievable in serum and pulmonary tissues are several 
times higher than the MICs for the most common 
currently infecting pneumococcal strains [56]. 
Thus the breakpoints of penicillin for non- 
meningeal strains are probably too conservative because 
patients with pneumococcal pneumonia having strains 
with a penicillin MIC < = 2  mg/L respond well to 
penicillin therapy [6]. 
For the same reasons, breakpoints of cefotaxime (or 
ceftriaxone) for non-meningeal strains are probably also 
inappropriate, since, to our knowledge, no clinical 
failures have been reported in the case of pneumonia 
with an MIC of cefotaxime < =2 mg/L [6,69]. 
However, it is important to know that there are 
several other cephalosporins such as cefaclor, cefixime 
or ceftazidime with very poor in vitro activity against 
penicillin-resistant pneumococci [44], and these drugs 
should not be used for treating pneumococcal infections, 
because clinical failures have occurred [69]. 
In addition, resistance to non-P-lactam antibiotics 
has often been associated with clinical failures, and 
there are several reports on the failure of erythromycin, 
tetracycline, co-trimoxazole and ciprofloxacin in the 
treatment of pneumococcal pneumonia caused by 
resistant strains [69-711. 
PNEUMONIA 
Patients with clinical pneumonia should be treated 
empirically, since laboratory testing requires at least 
24-48 h before the results are known. Moreover, despite 
extensive diagnostic testing and a presumptive clinical 
diagnosis, a causative agent is identified in only about 
50% of all cases of pneumonia. 
In the current era of antibiotic resistance, at least 
10 major considerations should be borne in mind when 
selecting initial empirical therapy for a patient with a 
presumptive pneumococcal pneumonia [69]. It will be 
important to: (1) know the local prevalence of drug- 
resistant pneumococci; (2) evaluate whether the patient 
is at higher risk for colonization-infection due to drug- 
resistant strains, as, for example, young age, day-care 
attendance, recent antimicrobial therapy, recent hos- 
pitalization and living in closed institutions such as 
nursing homes or prisons [69,72,73]; (3) think about 
the possibility of other common respiratory pathogens, 
and treat them empirically in severe pneumonia cases; 
(4) evaluate factors such as age, underlying conditions 
and severity of illness which may influence the etiology 
and prognosis of pneumonia; (5) rule out the possibility 
of concomitant pneumococcal meningitis, since the 
treatment options are substantially different; (6) evaluate 
whether the patient can benefit from hospitalization 
and supportive measures such as oxygen; (7) ask about 
the history of drug allergy; (8) think about the most 
appropriate dosage and route of the drug adminis- 
tration; (9) know the potential toxicity of the drug; and 
(10) consider economic costs. 
Therapy of presumptive pneumococcal pneu- 
monia should be initially chosen in each patient 
according to the severity of the infection. Thus, we 
define mild/moderate pneumonia as cases in which 
patients fulfill the criteria of low risk [74] and may be 
treated as outpatients. Severe pneumonia is defined as 
cases in patients who are over 50 years, and who exhibit 
co-morbid conditions or other factors associated with 
increased mortality [3,4,6], and who need to be treated 
in hospital. Table 2 shows the suggested treatment for 
adult pneumococcal pneumonia. 
Mildhoderate pneumonia (outpatient) 
On the basis of the current levels of resistance, high 
dosage of oral amoxycillin (50 mg/kg per day) may 
be the therapy of choice for patients in whom the 
pneumococcal etiology is strongly suggested by clinical 
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and radiological findings and, if possible, by sputum 
examination. 
However, an alternative drug may be required in 
some patients. Thus, oral amoxycillin-clavulanic acid 
(1 g/8 h) could be preferred in patients with chronic 
bronchitis in whom Haemophiltls infllrenzae may also be 
a common bacterial pathogen and is often B-lactamase 
positive. In patients with penicillin allergy, other drugs 
such as oral cefuroxime 750 mg/8-12 h (penicillin- 
allergic patients may have cross-allergy with cephalo- 
sporins) or a macrolide such as erythromycin 500 mg/ 
6 h or clarithromycin 500 mg/13 h should be con- 
sidered. When the oral route is not tolerated, intra- 
muscular procaine penicillin 1.3 m u /  12 h may be 
chosen. 
If there is a consistent doubt between diagnosis of 
pneumococcal and atypical pneumonia, one may 
decide to prescribe a macrolide. However, one should 
remember that high rates of erythromycin resistance in 
S. prieurnoriise were reported in some countries, and 
that strains with erythromycin resistance also show 
cross-resistance to the new macrolides [66,69]. 
Today, the new quinolones such as trovafloxacin or 
sparfloxacin, which have good activity against pneumo- 
cocci and atypical pathogens [19], should not be widely 
used in the treatment of mild/moderate pneumonia 
cases and probably should be reserved for severe 
pneumonia cases. 
Although co-trimoxazole has been used for the 
treatment of pneumonia in places in which pneumo- 
cocci show low resistance rates [75], in our opinion this 
drug should not be widely recommended for treating 
pneumonia, because of the high prevalence of resistant 
strains (Table 1). 
Severe pneumonia (inpatient) 
As mentioned above, patients who have severe pneu- 
monia should be hospitalized, and most of them will 
require parented antibiotics and other supportive 
measures. 
The initial empirical antibiotic therapy for severe 
pneumonia should include coverage of S. pnetlmoniae, 
the most common bacterium causing severe com- 
munity-acquired pneumonia, and other common 
respiratory pathogens [3,4]. Thus, intravenous ceft- 
riaxone 1-3 g/24 h, cefotaxime 1-3 g/8 h or amoxy- 
cillin-clavulanate 2 g/8 h could be the treatment of 
choice, and erythromycin 1 g/6 h should be added 
when Lqqionella or an atypical pathogen cannot reason- 
ably be ruled out. 
Alternative drugs may include a new cephalosporin 
such as cefpirome or cefepime, a carbapenem such as 
imipenem or meropenem, a glycopeptide such as 
vancomycin or teicoplanin, or a new quinolone such 
as trovafloxacin or sparfloxacin. We think that carba- 
penems and glycopeptides (e.g. vancomycin) should 
not be widely used for the initial empirical therapy of 
community-acquired pneumonia. 
However, in specific groups of patients, such as 
those with cancer and AIDS in whom other fastidious 
organisms may be involved, the initial therapy of choice 
for severe pneumonia should be a drug such as 
cefpirome, cefepime or a carbapenem, which also have 
activity against Psetldomonas aeriiLqitzosa. Other cephalo- 
sporins, such as cefiazidime, have little activity against 
penicillin-resistant pneumococci [44]. 
The use of some of the new quinolones such as 
trovafloxacin or sparfloxacin may play an important role 
as the initial empirical therapy in severe pneumonia 
cases in the near future, since they have very good 
activity against pneumococci and other common 
respiratory pathogens [19]. 
When the laboratory results are known, initial 
empirical antibiotic therapy should be switched to the 
narrowest-spectrum antibiotic according to the results 
of the susceptibility studies and the clinical response. 
Thus, standard dosage of penicillin G is the treatment 
of choice for susceptible pneumococci (MIC < =U.06 
mg/L). In addition, patients infected with pneumo- 
cocci with MICs for penicillin G of 0.12-2.0 mg/L 
may respond to intravenous penicillin G or ampicillin 
therapy, although it would be prudent to suggest high 
dosage (e.g. 200 000 U/kg per day of penicillin G) in 
order to reach higher serum and pulmonary levels. 
However, it is not known whether patients infected 
with pneumococci with MICs for penicillin G of 1 
mg/L or higher may be appropriately treated with 
penicillin, and continuation therapy should be based 
on the response to initial empirical therapy and the 
susceptibility to other drugs. 
Finally, some experimental studies in animals have 
suggested that the combination of amoxycillin and 
gentamicin or amoxycillin and fosfomycin may have 
synergistic effects against penicillin-resistant pneunio- 
coccal pneumonia [76,77], although, to our know- 
ledge, there are no reported clinical data with these 
combinations. 
MENINGITIS 
Patients with pneumococcal meningitis caused by 
strains with any degree of resistance (intermediate or 
high-level resistance) to penicillin do not respond to 
therapy with penicillin or ampicillin [66]. This is 
because intravenous penicillin achieves insufficient CSF 
levels to kill these pneumococcal strains [57]. 
Moreover, there have been several reports of 
cefotaxime or cefiriaxone failure in pneumococcal 
4S8  Cl in ica l  M ic rob io logy  and In fect ion,  Volume 5 Supplement  4 
meningitis caused by cefotaxime-resistant strains [54, 
631 in which most of the patients were treated with 
standard dosage (approximately 200 mg/kg per day). 
However, cefotaxime administered at higher dosage 
(approximately 300-400 mg/kg per day, with a maxi- 
mum of 24 g/day) may be effective at least for those 
with intermediate resistance [62]. In pedatric patients, 
the administration of high-dose cefotaxime may not 
always lead to suficient bactericidal activity in the 
CSF against strains with decreased susceptibility to 
cefotaxime [78]. Of special concern is the recent 
description of some pneumococcal strains with high- 
level resistance to cefotaxime [79]. 
The administration of vancomycin at a dosage of 
30mg/kg per day (the maximum dosage advised for 
adult patients) may not be appropriate for pneumo- 
coccal meningitis, since clinical failures have been 
reported [60]. These failures could be due to the highly 
variable concentrations of vancomycin achieved in the 
CSF, particularly when it is administered in association 
with dexamethasone [60]. In children, vancomycin can 
be given at higher dosage (60 mg/kg per day) and, to 
our knowledge, no clinical failure has been reported in 
pediatric pneumococcal meningitis treated with this 
drug. 
Chloramphenicol was considered to be an alter- 
native for penicillin-resistant pneumococcal meningitis. 
However, it has been shown that several penicillin- 
resistant pneumococci are also resistant to chloram- 
phenicol [12]. In addition, unsatisfactory results with 
chloramphenicol were observed in chloramphenicol- 
susceptible and penicillin-resistant pneumococcal 
meningitis [80]. These failures were related to poor 
bactericidal activity of chloramphenicol (increased 
MBCs) in penicillin-resistant strains when compared 
with penicillin-susceptible strains [80]. 
Antibiotic therapy for patients with pneumococcal 
meningitis must not be penicillin until the strain is 
known to be fully susceptible. Most of the recom- 
mended regimens are mainly based on susceptibility to 
cephalosporins. Results from experimental meningitis 
studies may help us to find better alternatives for the 
treatment of resistant pneumococcal meningitis. Table 
3 shows the suggested treatment for adult pneumo- 
coccal meningitis. 
Initial empirical therapy 
The initial empirical therapy for adult patients with 
pneumococcal meningitis (a purulent meningitis and 
a CSF Gram stain showing typical Gram-positive 
diplococci) should be a regimen including high- 
dose cefotaxime (300-400 mg/kg per day, maximum 
24 g/day) with or without vancomycin (30 mg/kg per 
day) [62,66]. 
We think that it would be prudent to suggest the 
combination of high-dose cefotaxime and vancomycin 
in places in which high-level cefotaxime resistance 
(MICs >=2  mg/L) has been observed. This com- 
bination is supported by the results of some experi- 
mental meningitis studies in which the combination of 
cephalosporin plus vancomycin was synergistic and 
more effective than either drug alone [63]. However, 
it is important to know that vancomycin (at the 
recommended dosage for adults) may achieve insuf- 
ficient CSF levels [60], and, therefore, combination 
with high-dose cefotaxime may be necessary. Vanco- 
mycin should be discontinued when laboratory results 
are known and the pneumococcal strain is susceptible 
to penicilhn or cephalosporins. 
Alternative regimens for initial empirical therapy 
include the combination of vancomycin and rifampin 
(900 mg/24 h), or the combination of cefotaxime and 
rifampin [66]. Rifampin should not be used as 
monotherapy, because of the rapid development of 
resistance. 
Therapy for known pneumococcal meningitis 
When laboratory results are known, any modification 
of the initial therapy should be based on antibiotic 
susceptibility and clinical status of the patient or the 
results of a control lumbar puncture. Most authorities 
recommend a second lumbar puncture in all patients 
with antibiotic-resistant pneumococcal meningitis. 
Thus, standard dosage of intravenous penicillin G 
remains the therapy of choice for patients having 
susceptible strains, and alternative drugs are only 
necessary in allergic patients (e.g. ceftriaxone or 
chloramphenicol or vancomycin plus rifampin). 
In contrast, penicillin G must not be administered 
to patients having strains with penicillin MICs >= 
0.12 mg/L. In such patients, the antibiotic therapy 
should be selected according to susceptibility to 
cephalosporins. 
Thus, standard dosage of intravenous cefotaxime 
(200 mg/kg per day) or ceftriaxone (50 mg/kg per day, 
maximum 4 g/day) may be given to patients with 
strains susceptible to these cephalosporins [66]. 
For patients with strains showing intermediate 
resistance to cefotaxime, therapy with high-dose cefo- 
taxime may be appropriate, and for patients with strains 
showing MICs of cefotaxime > =2 mg/L it would be 
prudent to continue the initial therapy (e.g. high-dose 
cefotaxime plus vancomycin) if the clinical evolution 
and the results of a control lumbar puncture are favorable. 
Any alternative therapy for cephalosporin-resistant 
pneumococcal meningitis is complicated and should 
be based on the results of susceptibility tests. Some 
available alternatives may be the combination of vanco- 
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mycin and rifampin, or meropenem or a new quino- 
lone (e.g. trovafloxacin). 
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